Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Evaluation Of Biomarkers For Cardiotoxicity Of Anthracyclin-based Chemotherapy

F. J. F. Broeyer, S. Osanto, H. J. Ritsema van Eck, A. Q. M. J. van Steijn, B. Ballieux, R. Schoemaker, A. Cohen, J. Burggraaf
Published 2008 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
IntroductionThe clinical assessment of the myocardial damage caused by anthracyclin (ANT)-therapy is difficult. Therefore a study was performed to evaluate non-invasive markers of anthracyclin-induced cardiac effects, with emphasis on course-to-course variation.MethodsEligible for study participation were patients, without known cardiologic abnormalities who did not use cardiotoxic medication (except for ANT-therapy), who had previously completed at least three cycles of anthracyclin-containing chemotherapy (n = 14) and patients who were ANT-naïve and who were scheduled to receive doxorubicin-containing chemotherapy (n = 12). Seven patients in this last group also completed at least three cycles and were available for follow-up assessments; thus a total population of 21 patients (12F/9M) completed at least three courses ANT-chemotherapy. In these patients blood samples and ECG-recordings were taken within 6 months after completion of ANT-therapy. In 12 patients (10F/2M) assessments were also done before, immediately afterwards and at 24 h after each course of ANT.Results and ConclusionsIn the patients who completed chemotherapy, NT-proBNP was 277% (n = 21; 95% CI: 86–661%, P < 0.001) higher compared to healthy volunteers. During the first course NT-proBNP rose 269% (n = 12; 167–409%, P < 0.0001) at 24 h post-administration. The linear corrected QT (QTcL) directly after the first administration of ANT increased by 9.56 ms (n = 12; 3.85–15.27, P < 0.001) and this prolongation was still present at 24 h, 11.48 ms (n = 12; 5.61–17.34, P < 0.0001). Both NT-proBNP and QTcL returned to baseline before the start of the next course and a similar pattern was observed during each course. NT-proBNP and QTcL may be useful markers for course-to-course evaluation of anthracyclin-induced cardiotoxicity.
This paper references
10.1053/HJ.1998.V136.89908
Elevated B-type natriuretic peptide levels after anthracycline administration.
T. Suzuki (1998)
10.1111/J.1527-5299.2004.03271.X
BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases.
M. Silver (2004)
10.1161/01.CIR.96.8.2641
Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.
S. Lipshultz (1997)
10.1016/j.ejheart.2004.03.009
Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction
G. Daugaard (2005)
Cardiac troponin I in patients with hematologic malignancies
E. Missov (1997)
10.1053/EUHJ.1999.1542
The relationship between QT intervals and mortality in ambulant patients with chronic heart failure. The united kingdom heart failure evaluation and assessment of risk trial (UK-HEART)
P. Brooksby (1999)
Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats.
R. Bennink (2004)
10.1002/PBC.10368
Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin
E. Kısmet (2004)
10.1158/1535-7163.MCT-06-CO1
Apoptosis and anthracycline cardiotoxicity
A. Thorburn (2006)
10.1016/J.CARDFAIL.2005.04.019
NT-ProBNP: the mechanism behind the marker.
C. Hall (2005)
Fiducial segment averaging to improve cardiac time interval estimates.
H. J. Ritsema van Eck (2002)
A more accurate method to estimate glomerular Wltration rate from serum creatinine: a new prediction equation. ModiWcation of diet in renal disease study group
AS Levey (1999)
10.1097/00000542-200506000-00006
Prolongation of QTc Interval after Postoperative Nausea and Vomiting Treatment by Droperidol or Ondansetron
B. Charbit (2005)
10.14712/18059694.2019.117
Anthracycline-induced cardiotoxicity.
R. Hrdina (2000)
10.1016/S0167-8140(00)00303-0
Circulating atrial natriuretic peptide plasma levels as a marker for cardiac damage after radiotherapy.
J. Wondergem (2001)
10.1002/cncr.11407
Congestive heart failure in patients treated with doxorubicin
S. Swain (2003)
10.5555/URI:PII:009377549290207H
The cardiotoxicity of chemotherapeutic drugs.
A. Allen (1992)
10.7326/0003-4819-91-5-710
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
10.1096/fasebj.11.12.9337145
Adriamycin cardiomyopathy: pathophysiology and prevention
P. Singal (1997)
10.1016/0305-7372(93)90036-Q
Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity.
A. P. Launchbury (1993)
10.1089/152308601750100641
Apoptosis in adriamycin cardiomyopathy and its modulation by probucol.
D. Kumar (2001)
10.1136/hrt.2005.071233
Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine
M. Weber (2006)
10.1124/pr.56.2.6
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
G. Minotti (2004)
Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis.
O. Arola (2000)
10.1373/CLINCHEM.2006.069575
Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.
S. Masson (2006)
10.1097/00045415-200209000-00007
Diagnosis of Myocardial Injury by Biochemical Markers: Problems and Promises
B. R. Malasky (2002)
10.1093/ANNONC/MDI152
cTnT can be a useful marker for early detection of anthracycline cardiotoxicity.
S. Kilickap (2005)
10.1161/01.CIR.0000130926.51766.CC
Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
D. Cardinale (2004)
10.1161/01.HYP.0000170140.36633.8f
Effect of Compensated Renal Dysfunction on Approved Heart Failure Markers: Direct Comparison of Brain Natriuretic Peptide (BNP) and N-Terminal Pro-BNP
A. Luchner (2005)
10.1002/MPO.2950250305
Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy.
F. Fink (1995)
10.1200/JCO.2001.19.10.2746
Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients.
M. T. Meinardi (2001)
10.7326/0003-4819-130-6-199903160-00002
A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
A. Levey (1999)



This paper is referenced by
10.1016/j.jacc.2017.09.1096
Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.
Hui-Ming Chang (2017)
10.3389/fonc.2014.00384
The Role of Notch in the Cardiovascular System: Potential Adverse Effects of Investigational Notch Inhibitors
P. Rizzo (2015)
10.1016/j.biopha.2016.06.037
Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells.
V. Alinejad (2016)
Review Article Cardiomyopathy Associated With Cancer Therapy
Anthony F. Yu (2014)
10.1007/s10741-018-9675-2
Biomarkers in cancer therapy related cardiac dysfunction (CTRCD)
R. Moudgil (2018)
10.1159/000329336
Adjuvant Systemic Therapy of Breast Cancer
F. Schuetz (2011)
10.1016/j.egja.2013.08.003
Effect of anthracyclines and isoflurane on QTc interval
Archana Venugopal (2014)
Prevention is Better than Cure - Preventing Chemotherapy Induced Cardiomyopathy
W. Qureshi (2013)
10.1007/S12156-010-0058-8
Drug-induced QT interval prolongation in cancer patients
T. Becker (2010)
10.1590/1414-431X20144189
Hormone therapy with tamoxifen reduces plasma levels of NT-B-type natriuretic peptide but does not change ventricular ejection fraction after chemotherapy in women with breast cancer
F. Silva (2015)
10.1042/CS20120620
Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury.
Hardip Sandhu (2014)
10.1155/2015/917606
Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors
A. Kirkham (2015)
10.24170/9-4-1828
Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy : biomarkers : detection and treatment of cardiotoxicity
G. Bacchiani (2012)
10.1016/S0716-8640(12)70380-2
Prevención de la cardiotoxicidad en pacientes que reciben quimioterapia
Florenzano Urzua Fernando (2012)
Powikłania kardiologiczne po chemioterapii - patomechanizm, diagnostyka, leczenie i zapobieganie
J. Dudziak (2009)
10.2217/fca.12.73
Using cardiac biomarkers and treating cardiotoxicity in cancer.
Alessandro Colombo (2013)
Orally administered anti-cancer nanocarriers loaded with therapeutic proteins
Ganesh Mahidhara (2012)
Modern diagnostic methods of anthracycline cardiotoxicity in lymphoma patients
Beata Kumiega (2012)
10.1186/1471-2407-11-373
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
M. Fiegl (2011)
10.1016/j.pcad.2010.04.002
Role of biomarkers in chemotherapy-induced cardiotoxicity.
D. Cardinale (2010)
10.1111/bcp.12429
Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients.
F. J. F. Broeyer (2014)
10.1016/j.clinbiochem.2014.10.013
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.
E. Christenson (2015)
10.7314/APJCP.2016.17.4.2301
Are Biomarkers Predictive of Anthracycline-Induced Cardiac Dysfunction?
A. Malik (2016)
10.1016/j.hfc.2016.12.009
Alternative Biomarkers for Combined Biology.
Y. Kim (2017)
10.1016/j.cardfail.2014.08.004
Cardiomyopathy associated with cancer therapy.
A. Yu (2014)
10.1016/J.JCECHO.2011.04.001
Approccio cardiologico al paziente sottoposto a trattamento antitumorale. Documento primo
L. Boccardi (2011)
10.1080/10408363.2016.1261270
Biomarkers for monitoring chemotherapy-induced cardiotoxicity
Liyun Cao (2017)
patients & modify CV risk factors Strategies for reducing cardiotoxicity : Anthracycline : Dose reduction , continuous infusion , liposomal doxorubicin , dexrazoxane Trastuzumab : Avoid concomitant anthracycline VSP inhibitors : Treat hypertension
Hui-Ming Chang ()
Short-term QT variability: A marker for reduced repolarization reserve in anthracyclin therapy
HJ Ritsema van Eck (2009)
10.1007/s11095-012-0845-y
Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab
J. G. C. Hasselt (2012)
10.2217/bmm.15.124
Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?
M. Chaudry (2016)
10.2147/IJN.S75877
Oral administration of iron-saturated bovine lactoferrin–loaded ceramic nanocapsules for breast cancer therapy and influence on iron and calcium metabolism
Ganesh Mahidhara (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar